
Graphs that paint the picture of HIV in SA
Eight million people are living with HIV with more than six million being on treatment.
Behind these big numbers lurk a universe of fascinating epidemiological dynamics.
In this special briefing, Spotlight editor Marcus Low unpacks what we know about the state of HIV in South Africa. This is part 1 of 3.
Four decades ago, hardly anyone in South Africa had HIV. Today, roughly one in eight people here are living with the virus. HIV has quite simply become a routine part of life in South Africa.
But thanks to the fact that antiretroviral treatment is keeping several million people alive, HIV is no longer the crisis it was at the turn of the century.
For many, the virus is still an all-too-real part of their lives. It still ranks among the country's top killers.
As we will see in this Spotlight special briefing, there is good and bad news. We have made massive progress in our collective fight against HIV, especially since around 2008. But, as positive as the big picture may be, there are also reasons to be worried.
In the 10 sections of this special briefing, we have used lots of graphs and an interactive table to liven things up. We have drawn almost entirely on estimates from Thembisa, the leading mathematical model of HIV in South Africa and also the basis for UNAIDS' country numbers.
The big picture
Total PLHIV in SA
Graphic: Spotlight
South Africa has the world's biggest HIV epidemic. Eight million people, or 12.8% of the population, lived with the virus in 2024. Despite the massive progress we've made in the last 20 years, this absolute number has kept increasing, and, at least by this measure, the epidemic has kept getting bigger.
But while more people are living with HIV, dramatically fewer people are dying of HIV-related causes than two decades ago - we've gone from 281 000 HIV-related deaths in 2005/06 to 53 000 in 2023/24. This is mainly because antiretroviral medicines have kept several million people alive who would otherwise now be dead.
The rate of new infections has also declined a lot, as shown in the above graph.
South Africa's HIV epidemic is closely entwined with our tuberculosis (TB) epidemic. This is because untreated HIV breaks down the immune system, which then makes people vulnerable to falling ill with TB.
Accordingly, TB is the top cause of HIV-related deaths in South Africa.
Recovering life expectancy
Just what a big deal HIV has been in South Africa is clear from estimates of life expectancy in the country.
As HIV killed more and more people through the nineties and early 2000s, life expectancy dropped precipitously from 63.2 in 1990 to 53.2 in 2004. But then, as antiretroviral treatment started keeping more and more people alive, it increased again. It stood at 66.1 in 2024.
Graphic: Spotlight
There is much history that is not captured in this graph. Perhaps most notably, the introduction of antiretroviral treatment in South Africa's public sector was intentionally delayed by the state's policy of Aids denialism under then-president Thabo Mbeki.
While the dramatic improvement from 2005 onward is impressive, life expectancy didn't have to drop as low as it did in the first place.
The blip you can see on the right of the graph is a result of the Covid-19 pandemic. While significant, the broader trend is driven by HIV and the recovery from HIV.
A massive treatment programme
Of the eight million people living with HIV in South Africa, about 6.2 million or roughly four in five, were on treatment in 2024.
This means South Africa has the world's most extensive HIV treatment programme by some distance. We take it somewhat for granted these days, but to treat so many people is a tremendous success story for which many healthcare workers, activists, government officials, donors, and others deserve great credit.
That said, it is concerning that about one in five people with the virus are not on treatment. Treatment is recommended for everyone living with the virus. Though we focus on treatment coverage here, these numbers are often split further into the UNAIDS 95-95-95 targets.
READ | Trump's HIV funding cuts will hit diabetes and cervical cancer treatment hard. Here's why
In 2024, 95% of people living with HIV had been diagnosed, 81.5% of those diagnosed were on treatment, and 92% of those on treatment were virally suppressed - meaning the amount of virus in their blood was below a low threshold.
The key takeaway from these numbers is that the most significant gap in South Africa's HIV response is in helping people who have already been diagnosed to start and stay on treatment.
*Check back tomorrow for part 2 of this series. You can also find the complete version of this #InTheSpotlight special briefing as a single page on the Spotlight website.
Note: All of the above graphs are based on outputs from version 4.8 of the Thembisa model published in March 2025.
We thank the Thembisa team for sharing their outputs so freely. Graphs were produced by Spotlight using the R package ggplot2. You are free to reuse and republish the graphs. For ease of use, you can download them as a Microsoft PowerPoint slide deck.
Technical note: The Thembisa model outputs include both stock and flow variables. This is why we have at some places written 2024 (for stock variables) and 2023/2024 (for flow variables). 2024 should be read as mid-2024. 2023/2024 should be read as the period from mid-2023 to mid-2024.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


News24
4 hours ago
- News24
Tumi Linx shares all things body positivity
Supplied Links talks about the importance of self-love and body positivity, especially for mothers. She shares her personal skin journey, revealing that she's struggled with eczema and dry skin. The influencer offers winter skin tips, recommending morula body cream mixed with body oil to moisturise. Content creator, pastry chef and businessperson, Boitumelo 'Tumi Linx' Links, who is known for beauty, fashion and being a proud mother, spoke to City Press about body positivity and shared some winter tips for people with dry skin. Speaking about loving her body after having two children, Links said she embraced the changes, sharing her journey on social media. The brand influencer said once a mother feels great about how she looks, she can show up in a more loving way for her children. 'With my first pregnancy, I was still young. I was 22 and my body snapped back quickly; I still looked in shape. But my second took its toll on me, so I started looking at myself in a different way because I was like, 'I wasn't like this'. But we are growing [older]; we are not getting any younger and our bodies don't react the same with pregnancies,' said Links. Supplied Links said she invested in her beauty because it worked for her as a public figure and in her work. She also invested in a gym, which helped with mental health, confidence and feeling her best. One thing about me [is that] I embrace even the smallest imperfections. Even if I can have stretch marks, I will show them on social media. The body changes, so you can't be hard on yourself because of imperfections. Tumi Linx 'Instead, turn them into something more positive instead of complaining, and do something about them. We are not perfect, so those little imperfections are what make me perfect as a person,' she said. On her skin journey, the 33-year-old said it had always been a work in progress, even before she had children. She shared that she suffered from eczema and dry skin for a long time and now, as a public figure, she has tried more ways to look her best. 'My skin has not always been perfect. For me, it was all about getting that glow and feeling great about myself and my appearance. I started investing in my skin seven years ago through Portia M oils. I struggled a lot with eczema, so I was trying to find the right product for my skin. I was looking for a product to use without getting irritated or inflamed,' she said. 'My friend introduced me to the Portia M oil. I started using it religiously and I started seeing the difference. I did not even know Portia [Mngomezulu, the founder of Portia M Skin Solutions] back then. 'I knew her when she started advertising the brand. So, I felt like reaching out and saying: 'Hey, you are doing wonders for us women who are struggling from skin conditions, and you found a solution',' said the brand influencer. Links' tips on how to keep dry skin moist this winter: Morula body cream mixed with morula body oil: 'Since I suffer from dry skin, I do not experience flaking or cracked skin. I stay moisturised, looking my best and glowing. Morula petroleum gel: It does the most. I apply it to my face before I sleep. Avoid taking showers; take baths instead in winter. I usually put a few drops of morula oil in my water and just soak myself. Links spoke to City Press at a Portia M Skin Solutions event, where the brand celebrated its 15-year milestone. The event, hosted by media personality Lerato Kganyago, was held in Sandton on Thursday evening. Mngomezulu hosted an intimate dinner with journalists, her clients and influencers who had testimonies about her brand. She shared that she did not randomly choose influencers on social media, but she worked with people who used the brand and had testimonials about it. Supplied Mngomezulu said she founded the brand after struggling with post-partum stretch marks, and her mother-in-law gave her a tip to use morula oil. She had not looked back since. As the oils also worked wonders for those around her, she decided to make a brand which she took to the retail stores. Talking about the brand's growth, Mngomezulu said she used a two-plate stove when she started making the products, but now the brand has automated machines. During the celebration, the mother of three introduced a repackaged version of Portia M's first product – morula oil – which launched her business in 2010. The oil now comes in a more sophisticated bottle. Mngomezulu laughed when she recalled that her clients told her that the oil worked wonders, but the packaging was not nice. She said she started with one retailer, Makro, in 2013, but now her products are in about 2 000 stores across 13 African countries, including a flagship store in Zambia.
Yahoo
a day ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data